Neumora Therapeutics (NASDAQ:NMRA) Posts Earnings Results, Beats Estimates By $0.02 EPS

Neumora Therapeutics (NASDAQ:NMRA – Get Free Report) issued its quarterly earnings data on Monday. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.02, FiscalAI reports. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million.

Neumora Therapeutics Stock Down 9.5%

NMRA stock opened at $0.33 on Wednesday. The company has a 50-day moving average of $0.56 and a two-hundred day moving average of $1.68. Neumora Therapeutics has a 52-week low of $0.30 and a 52-week high of $3.65. The company has a debt-to-equity ratio of 1.19, a quick ratio of 4.50 and a current ratio of 4.50.

Insider Activity at Neumora Therapeutics

In other news, insider Daljit Singh Aurora sold 67,741 shares of Neumora Therapeutics stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $1.51, for a total value of $102,288.91. Following the transaction, the insider directly owned 48,750 shares in the company, valued at approximately $73,612.50. The trade was a 58.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold 176,060 shares of company stock valued at $269,390 in the last 90 days. Insiders own 26.94% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on NMRA shares. Weiss Ratings cut Neumora Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Wall Street Zen upgraded Neumora Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, November 7th. Guggenheim reiterated a “buy” rating on shares of Neumora Therapeutics in a report on Tuesday. Finally, HC Wainwright reissued a “buy” rating on shares of Neumora Therapeutics in a research report on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $7.17.

View Our Latest Stock Analysis on Neumora Therapeutics

Neumora Therapeutics Company Profile

(Get Free Report)

Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing treatments for brain diseases. Founded in 2020 and headquartered in Watertown, Massachusetts, the company researches potential medicines for conditions including depression, schizophrenia and agitation associated with Alzheimer’s disease. The company combines neuroscience research with data science and other computational approaches to identify disease targets and develop drug candidates. Its pipeline includes investigational medicines designed to act on specific biological pathways involved in brain disorders; these products are under development and are not approved treatments.

Featured Stories

Earnings History for Neumora Therapeutics (NASDAQ:NMRA)

Receive News & Ratings for Neumora Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neumora Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.